OPRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
OptimizeRx Corp (OPRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. Despite its oversold RSI and potential for a short-term bounce, the lack of positive trading signals, declining financial performance, and neutral sentiment from analysts and insiders suggest that waiting for clearer growth signals or a more favorable entry point is prudent.
The stock is in a bearish trend with MACD below zero and negatively expanding, RSI indicating oversold conditions at 15.694, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at 8.408, and resistance is at 9.978. Pre-market price is 8.375, close to support levels.
RSI indicates oversold conditions, which could lead to a short-term bounce. Gross margin improved by 8.76% YoY in Q3 2025.
Analyst sentiment is neutral with a lowered price target. No significant hedge fund or insider activity. No recent news or congress trading data to support a positive outlook.
In Q3 2025, revenue increased by 22.33% YoY to $26.07M, but net income dropped by 108.54% YoY to $779K, and EPS fell by 108% YoY to 0.04. Gross margin improved to 63.05%, up 8.76% YoY.
Stephens analyst Jeff Garro lowered the price target from $20 to $17 and maintained an Equal Weight rating, citing a balanced risk/reward profile after a 200% YTD increase in share price.
